A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 3-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)
A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 3-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 3-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)
Approximately 350 sites globally will participate in this study. Approximately 970 participants will be randomized to AZD6793 or Placebo. Following CSP V.3.0, participants will be randomized in a 1:1:1 ratio of two doses of AZD6793 vs Placebo.
Inclusion Criteria:
Exclusion Criteria:
information.center@astrazeneca.com1-877-240-9479
CABA, C1426, Argentina
Ciudad Autónoma de Bs As, C1182ACD, Argentina
Ciudad de Buenos Aires, 1060, Argentina
Ciudad de Buenos Aires, C1094AAD, Argentina
Chile, 7770484, Chile
Nyíregyháza-Sóstóhegy, 4481, Hungary
Ginowan-shi, 901-2214, Japan
Hachioji-shi, 193-0998, Japan
Izumi-shi, 594-0073, Japan
Kasuga-shi, 816-0813, Japan
Kawasaki-shi, 216-8511, Japan
Kiyosu-shi, 452-0001, Japan
Kusatsu-shi, 525-8585, Japan
Minokamo Shi, 505-8510, Japan
Mizunami-shi, 509-6134, Japan
Sagamihara-shi, 252-0143, Japan
Sasebo-shi, 857-8511, Japan
Shimotsuga-gun, 321-0293, Japan
Shinjuku-ku, 160-0023, Japan
Tachikawa-shi, 190-8531, Japan
Toon-shi, 791-0281, Japan
Yokkaichi-shi, 510-8561, Japan
Yung Kang City, 71044, Taiwan